Source comparison
Tesamorelin + Ipamorelin Blend Oral vs Injectable: Route Comparison
The following table summarizes the key pharmacokinetic, practical, and efficacy differences between oral and injectable tesamorelin + ipamorelin formulations based on peer-reviewed peptide pharmacology and clinical trial data. Subcutaneous Injectable 70–85% 1–
This comparison does not assign a generated winner or score.
- The following table summarizes the key pharmacokinetic, practical, and efficacy differences between oral and injectable tesamorelin + ipamorelin formulations based on peer-reviewed peptide pharmacology and clinical trial data.
- Subcutaneous Injectable
- 70–85%
- 1–2mg tesamorelin + 200–300mcg ipamorelin
- 30–60 minutes
- 200–400% increase within 90 minutes
- $12–18 per effective dose
- Gold standard for research. Intact peptide delivery, reproducible kinetics, consistent GH response
- Oral (Capsule/Tablet)
- <5% (often <1%)
- 10–20mg claimed (compensatory dosing)
- Erratic or unmeasurable
- Inconsistent, often no significant change
- $40–80+ per theoretical dose
- Poor research utility. Gastric degradation, minimal systemic exposure, high inter-subject variability
- Subcutaneous injection remains the validated delivery route for growth hormone secretagogues because it preserves peptide structure through the entire pathway from vial to receptor. Oral formulations cannot overcome the enzymatic and pH barriers inherent to gastrointestinal absorption. Higher nominal doses do not compensate for near-total degradation.